Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics
The use of poly (ADP-ribose) polymerase inhibitors (PARPi) revolutionized the treatment of
BRCA-mutated cancers. Identifying patients exhibiting homologous recombination …
BRCA-mutated cancers. Identifying patients exhibiting homologous recombination …
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Homologous recombination deficiency (HRD) is a predictive biomarker for poly (ADP-ribose)
polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA …
polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA …
Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid
C Roussel-Simonin, F Blanc-Durand, R Tang… - Molecular Cancer, 2023 - Springer
Background Knowing the homologous recombination deficiency (HRD) status in advanced
epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by …
epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by …
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma …
A Kime, G Bataillon, I Treilleux… - … of Pathology & …, 2024 - meridian.allenpress.com
Context.—A correlation between the morphology of ovarian high-grade serous carcinomas
(HGSOCs) and BRCA mutations has been previously reported. Objective.—To investigate …
(HGSOCs) and BRCA mutations has been previously reported. Objective.—To investigate …
The Molecular Classification of Ovarian Cancer and Implication for Treatment
Ovarian cancers are divided into epithelial carcinomas, representing the majority of
malignant ovarian tumours in adult women (90%) and non-epithelial carcinomas. In each …
malignant ovarian tumours in adult women (90%) and non-epithelial carcinomas. In each …
Enjeux et complexité de l'élaboration de signatures géniques des défauts de la recombinaison homologue comme biomarqueur à visée thérapeutique en oncologie
D San - 2023 - hal.science
Le développement de thérapies ciblées sur les voies oncogéniques et des
immunothérapies a révolutionné le traitement des patients atteints de cancer. Ces …
immunothérapies a révolutionné le traitement des patients atteints de cancer. Ces …
of Ovarian Cancer and Implication
M Kossaï, M Cavaille… - Pathology of the Ovary …, 2023 - books.google.com
Ovarian cancers are divided into epithelial carcinomas, representing the majority of
malignant ovarian tumours in adult women (90%) and non-epithelial carcinomas. In each …
malignant ovarian tumours in adult women (90%) and non-epithelial carcinomas. In each …